hengrui glp-1 China Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) Kailera says obesity pill succeeds

In the SURMOUNT-1 trial, tirzepatide produced average weight reductions of 15.0%, 19.5%, and 20.9% at studied doses compared with 3.1% with placebo over 72 weeks

With a GLP-1 fusion protein containing an albumin binding domain, Yousefpour and colleagues 61 showed that the longer length and rigidity of the helical linker effectively kept the albumin, which is bound to the albumin binding domain, far enough from GLP1 to prevent it from interfering with its binding to the GLP1-R

Like any medication, they carry risks, but most are mild and manageable

CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice

2022;Jensen et al